FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA oncologists discuss niraparib for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
